BEL AIR CENTER

early diagnosis • best treatment • better quality of life • finding a cure

PHAEUROPE & Global

PULMONARY HYPERTENSION ASSOCIATION

2024

INTRODUCTION

PHA Europe serves as the umbrella association for pulmonary hypertension (PH) across Europe. Originating in Vienna, Austria, in 2003, it unites 41 PH patient associations from 36 different countries. The organization's activities are overseen by the Board of Directors, elected biennially by the General Assembly, and administered by dedicated staff members. The Board and staff comprise individuals with diverse nationalities and language proficiencies, bringing extensive expertise in areas such as patient advocacy, business, politics, law, accounting, IT, and project management. A significant number of board and staff members have personal connections to PH, either through direct experience or through family and friends.

PHA Europe has over the years become a recognized stakeholder in Europe for PH. It has close working relationships with:

- EU institutions (EU Parliament, EU Commission, European Medicines Agency)
- European Reference Networks (ERN-Lung, ERN-Transplant-Child)
- Main EU level public health organizations (EPF, ESOT, EURORDIS, ELF)
- European federations for diseases of the lungs, heart, liver, kidney (EFA, ELPA, EKHA, EFKP, EHN, CCE, CCE…)
- Public health multi-stakeholder platforms dedicated to access issues (PACT)
- European professional societies for cardiology and pulmonology (ESC, ERS)
- Research organisations (PVRI)
- Individual members of the European PH scientific community
- Main companies in the pharmaceutical field involved in the development/distribution of PH drugs
- Other PH associations around the world

The 4 “pillars” on which PHA Europe’s activity rests are: awareness, advocacy, capacity building and information.

- ✓ **AWARENESS -** to raise the profile of PH, still a little known condition which is diagnosed and treated very late, with dramatic consequences for patients
- ✓ **CAPACITY BUILDING** - to empower our member associations to reach the level of skills, knowledge, activity and services to effectively support PH patients and family members
- ✓ **ADVOCACY** - to strive for best standards of care and access to approved treatments and surgery as well as medical intervention at an affordable cost for all PH patients in Europe
- ✓ **INFORMATION** - to disseminate up-to-date and easy to understand news about PHA Europe and PH generally with its member associations, other NGOs, HCPs, industry and all other relevant stakeholders through various communication channels, including own webpage and social media channels.

PHA EUROPE'S MAIN ACTIVITIES

Awareness

PH remains a little known illness, with an average of 2-3 years passing from the onset of initial symptoms to a conclusive diagnosis. PHA Europe is actively engaged in promoting awareness of this condition. In 2024, our efforts in this regard centered around two key initiatives: observing World PH Day and Awareness Month in November, along with running miscellaneous social media campaigns.

World PH Day

World PH Day (WPHD) is an annual campaign, the aim of which is to achieve greater visibility for the condition. The first World PH Day (WPHD) was held in Madrid in 2012, on the initiative of the Spanish PH association ANHP. The year 2024 marked the 12th anniversary of World Pulmonary Hypertension Day (WPHD), with PHA Europe continuing its significant role as the global coordinator for the events of this meaningful day. Taking on the coordination responsibility was not only a great honor but also entailed substantial responsibility, which we once again successfully navigated. The impact analysis reveals that the coordinated global campaign on Facebook and Instagram in the previous year resulted in approximately 6.5 million impressions. This underscores the effectiveness of our efforts to strengthen awareness of pulmonary hypertension worldwide. Nearly all European PH associations hosted enlightening activities. The challenges associated with the global coordination of World PH Day are immense, yet in 2024, we once again triumphed over them. This success is reflected not only in quantitative reach but also in the quality of awareness campaigns launched by our member organizations on social media in November. PHA Europe was collaborating with PHA to raise awareness for Pulmonary Hypertension (PH) during the Awareness Month of November. Tailorable templates have been created for sharing on social media. There are two main annual awareness campaigns: World PH Day (May 5th) and Awareness Month in November. PHA Europe and PHA worked closely together on both events. PHA Europe leads World PH Day, while PHA spearheads the Awareness Month project. In 2024 we were celebrating the resilient spirit of the PH community. Our campaign called «Let's Breathe in Unity for the Global PH Community», highlighted the importance of joining forces with all PH communities in the world. By providing pre-defined posts for our associations, we ensured a cohesive and effective presence throughout the month. Maintaining this global coordination role requires not only dedication but also continuous adaptation to the evolving digital landscape and the needs of our member organizations. With pride, we reflect on the year 2024, confident that our collective efforts will continue to contribute to promoting understanding of pulmonary hypertension and effecting positive changes worldwide.

- WPHD in Europe and all over the worlds is coordinated by PHA Europe staff. As of 2021 PHA Europe has taken over the coordination globally: new webpage (WorldPHDay.org) has been launched and managed by us both in English and Spanish, ready-to-use materials were delivered in both of these languages. More specifically, in Europe our member associations apply to take part and submit projects for approval and funding. The campaign has a common theme and a professionally developed toolkit, including common artwork for T-shirts, banners, sea flags, merchandising and other materials, as well as templates for press conferences, flash mobs and other events being held for the occasion.
- WPHD started out as a campaign targeted at the general population, but has increasingly seen the involvement of national political and health authorities, academia, health care professionals and celebrities. To foster these activities an online petition has been launched for immediate actions to ensure access to treatments.
- WPHD has contributed to the empowerment of the member associations by providing them with the opportunity to hold national awareness raising, educational, advocacy and fundraising activities.

- We hosted a global WPHD webinar attended by participants worldwide. Professor Ardeschir Ghofrani delivered an engaging and inspirational presentation titled 'ENon-PAH PH, what is what and which treatments are recommended'. The webinar was streamed through our advanced virtual conference platform, Bel Air Center, designed to facilitate the exchange of knowledge and connections among patients, experts, and pharmaceutical companies.

- The World PH Day events always have the same message: we are a big family!

Capacity Building

Capacity building is another very important part of PHA Europe's activities. Our organisation's ultimate goal is to put in place a strong European PH community consisting of empowered national associations, working together for the PH cause.

White Spots & Member Support Program

The White Spot Program is a program where we help to establish a PH association in a country where no association exists. Once established, the Member Support Program (MSP) takes over. In the MSP, we help associations to mature. The need for The White Spot program was greatly reduced in recent years, as there are almost no countries in Europe of significant size left without an association. The MSP is, hence, the most active program of these two at the moment.

Key info:

- The White Spot Program has been very successful, as we have helped establish more than 20 national PH associations in Europe.
- We have developed a guide, which describes step by step what actions need to be taken in order to start an association. Because of this structured approach, an association can be started by one dedicated person alone, as long as the person gets assistance from PHA Europe.
- The most popular activity in the MSP has been the implementation of a new web pages. This is due to the fact that PHA Europe themselves got new pages, and that a template was developed as a consequence. So now, several of PHA Europe's members have new pages with the same look and feel as their umbrella association. We will continue to replace several of the members' webpages in the future.
- The MSP has been used to create new image brochures for several of our members in 2024. The brochures are based on a template developed by PH Austria. More associations will follow in 2025.
- Many associations have established a hotline service due to the MSP

Fellowship

PHA Europe's official working language is English and, as the organisation expanded over the years to include more and more countries, communication started to become a critical issue with those associations where neither Board members nor volunteers had a good command of this language. Thanks to our "Fellowship" program, PHA Europe has been able to provide these associations with a part time English speaking assistant. The program started in 2013 with nine Fellows; in 2024 we were able to support 19 patient associations with a Fellow. The program has been very successful in ensuring a smooth flow of communication and actively engaging our member associations in common activities. The fellows help with translations and support the associations on the basis of 8-10 hours per week.

- The following countries were supported: Belarus, Bosnia & Herzegovina, 2x Bulgaria, Croatia, Czech Repuplic, Hungary, Israel, Latvia, North Macedonia, Portugal, Serbia, Slovenia, 3x Spain, 2x Ukraine.

- The program has been very successful and has considerably improved communications, as well as the level of engagement of the national associations in common European projects.
- In 2025, we would like to maintain at least the current level of support and possibly increase with 1 fellow in Romania and Poland. The total number will then be 21 fellows.
- Goal is to make it possible to have a fellow for every member association of PHA Europe. At the moment we have 41 associations in 36 countries.

APHEC (Annual PH European Conference)

The Annual PH European Conference, APHEC 2024, again took place in Castelldefels, Barcelona, from November 6th to 10th. The conference brought together participants from numerous countries, representing PH associations outside Europe. The conference served as a platform for the exchange of expertise, experiences, and best practices in the field of pulmonary hypertension (PH). Distinguished speakers from various parts of the world contributed to a diverse discussion, shedding light on the latest developments in PH research, diagnosis, and treatment. A highlight of the event was the acceptance of new member associations, further strengthening the international reach and collaboration within the PH community. The conference also provided space for interactions with representatives from the pharmaceutical industry, who presented their latest developments and research approaches. These partnerships are crucial for advancements in medical care and therapy for PH. We extend our gratitude to all participants, including our member associations, distinguished speakers, and pharmaceutical representatives. By joining forces in our collective effort, we affirm that we stand together to address the challenges of pulmonary hypertension and raise awareness of this life-altering condition. APHEC 2024 was not only a platform for knowledge exchange but also a step forward in global collaboration for better care of patients with pulmonary hypertension.

Bel Air Club

Throughout the years of the pandemic, we have conducted virtual meetings, utilizing a virtual conference center created specifically for this purpose. In this virtual environment, we hosted presentations and explored booths of industry partners and associations. Additionally, participants had the option to engage in chats or take part in informal video conferences with one another. These virtual conferences proved highly successful, prompting us to leverage the benefits of our virtual conference center even after the pandemic subsided. As a result, we are actively evolving this virtual center into a PH hub accessible to patients, caregivers, healthcare professionals (HCPs), and other PH stakeholders worldwide, and we've named it our Bel Air Club. Recognizing that the club will be frequented by individuals of diverse nationalities, we have incorporated translation features. Furthermore, we are diligently working on subtitling presentations, enhancing the social gathering space, establishing an area dedicated to artworks created by PH patients and HCPs, and more.

Information materials and resources

Sharing helpful information is a key part of building our capabilities. Learn more about it in the "Information & Education" section.

Advocacy activities

PHA Europe’s mission is to achieve best standards of care, equal and affordable access to treatment/surgery and better quality of life for all PH patients in Europe, including the very important and largely unmet psycho-social support needs. Despite enormous progress in past years, there are still very wide disparities and inequalities in Europe: not all approved drugs are available in all countries across Europe and there are countries where no drugs at all are accessible and where expert centers/surgical facilities do not exist.

- PHA Europe is active in its support to national advocacy activities by providing guidance and strategic advice, by writing letters and participating in meetings with national health authorities and other relevant stakeholders and by engaging in one to one talks with representatives of the pharma industry
- Since 2017 PHA Europe has organised and supported the training of physicians from countries with serious drug access problems, the rationale being that these physicians can transfer the knowledge gained to colleagues in their own countries and can become future PH "champions" at national level. Unfortunately, this project has been put on hold due to the pandemic, but we hope in restarting it.
- At European level PHA Europe has been active, within larger and very influential organisations (EURORDIS, EPF, PACT, ESOT) and within the main professional societies (ERS, ELF, ESC, PVRI) in contributing to the discussions on policies to reduce waste/improve investment in healthcare, in involving the patients in policy making, including the patients in the drug regulatory processes, including the patients in definition of clinical guidelines, including patients' goals in scientific agendas. PHA Europe also plays an important role in ERN-Lung and was elected in the Medical Steering Committee.
- For the future, there is an absolute need to define what is really relevant in terms of outcomes from the patient's point of view. The different degrees of access to therapies leads to an adaptation of what is to be expected in real life at country level. This will also be conducive to evaluate the impact of the disease and of the available therapies, which is an extremely powerful tool in the advocacy field.
- Likewise, PHA Europe intends to collect the expertise and experience of its members in order to contribute to the definition of clinical endpoints and composite endpoints that are as relevant for patients as for HTA agencies and physicians.
- PHA Europe has also been very active in organ donation and transplant issues. Its 2015 Call to Action was endorsed by 90+ national and European organisations and a PHA Europe initiated European Parliament (EP) event was held in 2016, whose media reach was over 70M. The EP event in 2016 was followed up with meetings in 2017 with the federations for heart, lung, liver and kidney diseases; a social awareness event was organized at the European Parliament in February, 2019 with the presence of members of the European Parliament and other stakeholders. Despite previous efforts organ donation and transplantation is still problematic in many countries. In order to identify the critical points to be improved we plan to launch a survey within our members.

Workshops and conferences

PHA Europe representatives are increasingly invited to participate in significant congresses, symposia, workshops, and other essential events. They are also actively engaged in the work of advisory committees, task forces, and working groups within prominent scientific societies, EU regulatory agencies, and European NGOs.

- Attending these scientific events offers PHA Europe valuable opportunities to both raise awareness of the disease and stay up-to-date with the latest developments in pulmonary hypertension (PH) and public health-related issues.

- Involvement in advisory committees, task forces, or working groups of prestigious organizations empowers us to advocate effectively and contribute to the formulation of health policies.

- Our training workshops play a pivotal role in education, equipping attendees to become more effective advocates at both the European and national levels.

- As members of larger organizations such as EURORDIS, the EUROPEAN PATIENT'S FORUM, and the EUROPEAN PUBLIC HEALTH ALLIANCE, we enjoy numerous benefits, including the ability to shed light on PH issues to broader audiences.

- Ultimately, all these meetings offer excellent networking opportunities, a vital element in our efforts to raise awareness and advocate for change.

Following, you will find a listing of events that PHA Europe was present at in 2024:

PVRI congress

At the 2023 PVRI Congress in London, attended by more than a thousand PH experts from more than 100 countries, global inequalities in pulmonary hypertension care were strongly highlighted, with many regions — particularly in Africa and South America — facing severe shortages of PH centers and limited access to treatment. Despite these challenges, the congress also showcased impressive expertise from clinicians worldwide, demonstrating that high-quality PH care is achievable even in resource-limited settings. Scientific sessions covered new therapeutic developments, innovative trial designs, and the promising future approval of Sotatercept. PHA Europe maintained an active presence with an exhibition booth, strengthened international collaborations, and helped raise awareness of its advocacy efforts. A major contribution was the PH Global Patient and Carer Survey (PH GPS), which PHA Europe supported through translation work and broad dissemination, resulting in over 3,300 respondents and significant visibility at the event.

SAPH2024

At SAPH2024 — the 17th annual conference held in Riyadh from 15–17 February 2024 — leading global experts in pulmonary hypertension gathered to present the latest scientific developments, including promising new treatments such as Sotatercept and emerging therapies for PH-ILD. PHA Europe was represented by Hall Skaara, who delivered a presentation on the organisation's work and introduced the newly launched virtual PH platform, the Bel Air Center (BAC). In addition to scientific sessions, foreign speakers were invited to visit the national PH centre at King Faisal Specialist Hospital — highlighting local infrastructure and research efforts, including genome sequencing for PH patients. The conference featured case presentations from Middle-East clinicians, underscoring that PH care and access to all approved treatments — including transplant programs — are available locally. The overall feedback emphasised strong international collaboration, high organisational quality, and a warm, welcoming environment for participants.

EPF's GAM

At EPF's Annual General Meeting in Brussels on 13–14 April 2024, the first day was dedicated to an in-depth thematic session on the growing role of Artificial Intelligence (AI) in healthcare. Presentations addressed both opportunities and risks, highlighting the need for strong regulatory and ethical frameworks, while EPF introduced its AI Capacity Building Programme and shared its position paper on responsible AI use for patients. The second day covered EPF's statutory matters, including a review of 2023 activities, financial reporting, and updates on new member applications. EPF also presented its work plan for 2024, which prioritises meaningful patient involvement, digital health and data policy, tackling health inequalities, improving patient safety, and strengthening the patient-advocacy community across Europe. The meeting offered valuable opportunities for networking, knowledge exchange, and strengthening collaboration among patient organisations, including PHA Europe.

IMPAHCT 2024

At IMPAHCT 2024 in Barcelona, around 150 pulmonary hypertension specialists from across Europe gathered for the sixth edition of the meeting, where PHA Europe was represented by Hall Skaara as the sole patient advocate. The conference opened with sessions on diagnosis, classification, and the growing challenge of managing patients with overlapping comorbidities or unclear PH categories. Experts also presented emerging biomarker research, including investigations into NT-ProBMP, although no single definitive diagnostic marker has yet been identified. A dedicated segment focused on the patient perspective, featuring results from a multicountry study on PH and PH-ILD patients, underscoring the profound impact on quality of life, work, relationships, and emotional well-being. During the roundtable, Hall emphasised the importance of integrating patient-reported outcomes and quality-of-life measures, such as PROMs like emPHasis-10, into clinical decision-making and future clinical trials. The remaining sessions included "coffee with the expert" discussions, updates on PAH management strategies, lectures on right-ventricular function, and global perspectives on PH treatment. The meeting concluded with a strong focus on patients with PH associated with interstitial lung disease (PH-ILD), highlighting the seriousness of this subgroup and the limited treatment options currently available. Overall, IMPAHCT 2024 successfully combined high-level scientific content with meaningful patient-centred dialogue, reinforcing the need for improved classification, better biomarkers, stronger patient involvement, and more attention to under-served PH populations.

World's 7th PH Symposium

At the 7th WSPH in Barcelona (28 June–1 July 2024), more than 1,500 experts, clinicians, researchers and patient representatives gathered to shape future directions in pulmonary hypertension (PH) care and research. PHA Europe was strongly present — six delegates attended and the organisation maintained an informational stand — and played a central role through membership of Task Force 1 – Patient Perspective. This task force had the honour of delivering the opening presentation, titled "The Patient Perspective," setting the tone for the entire symposium by emphasising the importance of patient involvement in defining research priorities, treatment guidelines, and healthcare policies. The symposium offered valuable opportunity for networking and building collaborations between patient associations, healthcare professionals, researchers and policymakers. The active participation of patients highlighted the evolving role of patient voices in PH care and research — reinforcing that meaningful patient input is vital for improving treatments, guideline development, and overall quality of life for people living with PH.

International PHA conference

At the 15th International PH Conference in Indianapolis in August 2024, roughly 1,100 healthcare professionals, researchers, patients and advocates from around the world gathered under the theme "Stronger Together." The global PH community met the evening before the conference to share regional challenges and strategies, and PHA Europe was represented by Hall Skaara, who presented the organisation's "Call to Action" and outlined key priorities for Europe. During the conference, a joint session by the Pulmonary Vascular Research Institute (PVRI) and the Pulmonary Hypertension Association (PHA) highlighted the growing importance of real-world evidence as a complement to traditional clinical trials, emphasising how registry data can help better reflect diverse patient populations. Alongside the scientific and clinical programme, attendees took part in networking activities, support-group meetings and community-building sessions, including a patient-focused fashion show celebrating long-term PH survivors. Overall, the conference underscored the value of global collaboration, meaningful patient involvement and the integration of real-world data in shaping the future of PH care and advocacy.

ELF Networking Day

At the ELF Networking Day on 7 September 2024 — held just before the official start of ERS Congress — patient organisations, advocates and health professionals from across Europe and beyond gathered to focus on “Driving policy and healthcare change.” Participants heard a powerful keynote from a senior WHO representative emphasising the critical link between clean air and respiratory health, and how patients can be agents of policy change. The day featured presentations from several patient organisations highlighting campaigns on COPD awareness, lung cancer, and holistic respiratory care; a patient-organization video showcase; and interactive breakout sessions on themes such as disease visibility, access to treatment, digital health and AI. Feedback showed that many participants valued the opportunity for networking and exchange, and suggested future improvements such as more patient-level involvement and stronger interaction between patient organisations and other stakeholders. The event underscored the growing role of patient advocacy in shaping lung-health policy, and reinforced the need for collaboration, awareness, and concrete action on key issues like clean air, access to care, and equitable treatment for respiratory diseases.

ERS 2024 Congress

At the ERS Congress 2024 in Vienna, which gathered nearly 20,000 delegates both onsite and online, Hall Skaara represented PHA Europe, engaging in a wide range of sessions and networking opportunities across respiratory health and pulmonary hypertension topics. The congress opened with a keynote by a leading futurist, focusing on the balance between technological innovation — particularly in digital health and AI — and human-centred care. Hall participated in sessions of the European Lung Foundation (ELF) Patient Advisory Committee (PAC / IPAC / PH-PAG), contributed to discussions on digital health, air-quality policy and patient inclusion, and met with global stakeholders including a representative from World Health Organization (WHO). Outside the official programme, Hall attended an event on clinical trials where new therapies such as seralutinib and PROSERA were presented, followed by a workshop addressing patient recruitment challenges in PH trials. In sum, ERS 2024 offered valuable opportunities for exchange of scientific knowledge, advocacy of patient perspectives, and strengthening cooperation between patient organizations, researchers, clinicians and global health stakeholders.

Information & Education

The dissemination of up-to-date information about pulmonary hypertension is another important part of PHA Europe’s activities. It is instrumental both in raising greater awareness of the disease and in the empowerment of the national associations.

Journals

The Mariposa journal stands as our flagship "product." It is published biannually, with the entire summer edition dedicated to World PH Day. Within these summer releases, readers can delve into details about specific World PH Day projects at both the European and global levels, as well as on a country-specific basis. For more information, please explore the World PH Day section on our website. On the other hand, the winter edition comprehensively covers all activities undertaken by PHA Europe or its member associations. Distribution of the journal occurs through electronic channels such as our webpage and social media, as well as via email. Additionally, printed copies are distributed to physicians, decision-makers, representatives of pharmaceutical companies, and other stakeholders. The graphic design, printing, and distribution of these copies are centralized processes.

Website, social media and online platforms

One of the primary objectives of PHA Europe is to furnish current and dependable information, and there is no better resource for this than a meticulously managed and regularly updated website. We place a strong emphasis on reliability, ensuring that our entries on pulmonary hypertension have been validated. Our news section serves as a valuable source of information, providing updates on conferences, congresses, learning opportunities, and new publications.

While we regard our website as a cornerstone of information, we have recognized the vital role of communication through social media. Consequently, we have directed more attention and invested additional effort in managing these platforms. The metrics associated with our activities are steadily increasing across all social media networks. Fortunately, this mirrors the broader trend seen in the activities of national associations, and the success is quantifiable and prominently visible. This is primarily evident in the escalating number of posts published on social networks. Recognizing the tremendous potential offered by social networks, associations, in collaboration with PHA Europe, are achieving substantial results.

Social media activities have also played a pivotal role in our two main projects: World PH Day and Awareness Month November.

In the following pages, you will find a listing of events that PHA Europe was also present at in 2024:

Vienna, Austria • January 23-24
PHA EUROPE CORPORATE MEETING
The board and staff ran a yearly meeting followed by a corporate meeting with industry partners highlighting plans for 2024.

London, England • January 31 - February 3
PVRI Annual conference
Hall attended PVRI's annual conference, where PHA Europe hosted a stand to distribute materials and engage with conference participants.

Riyadh, Saudi Arabia • February 14-18
SAPH 2024
Hall participated in the 17th annual PH conference in Riyadh, where he presented the work of PHA Europe and introduced the newly launched virtual PH platform, the Bel Air Center. The programme also included a visit to the King Faisal Specialist Hospital and Research Centre, with a guided tour of its PH facilities and research activities..

Brussels, Belgium • April 13-14
EPF's AGM
Hall participated in EPF's annual general meeting. The two-day event opened with a dedicated focus on Artificial Intelligence (AI), exploring its opportunities and challenges in healthcare, and continued on the second day with the formal AGM proceedings.

Barcelona, Spain • April 26
FERRER'S EVENT IMPAHCT
Hall attended Ferrer's IMPAHCT meeting, which brought together 150 PH specialists from around the world. As the sole patient advocate present, he delivered a presentation highlighting the patient perspective, addressing quality-of-life challenges, and advocating for greater patient involvement in clinical and decision-making processes.

Amsterdam, The Netherlands • June 18-19
INTERNATIONAL RESPIRATORY COALITION
Eva participated in the IR Congress alongside other self-help groups representing ILD and sarcoidosis. The meeting emphasised the importance of multidisciplinary collaboration and how such coordinated approaches can significantly improve respiratory outcomes.

Barcelona, Spain • June 28 - July 1
WOLRD'S 7TH PH SYMPOSIUM
Selected board and staff members participated in the World PH Symposium, attended by more than 1,500 leading experts in the field. PHA Europe hosted a stand, distributing materials and engaging with visitors. Hall also took part in Task Force 1 and contributed to their presentation, "The Patient Perspective." The symposium plays a crucial role in shaping future guidelines for PH treatment and management, and participating in these discussions provided valuable insight into upcoming developments and how patient input can be more effectively integrated into clinical guidance.

Indianapolis, Indiana, USA • August 15-18
PHA'S INTERNATIONAL CONFERENCE
Hall attended the 15th International PH Conference, where he co-led a session with a physician on "Men's Health and Wellness." The conference is unique in that it brings together both healthcare professionals and patients, creating a valuable environment for shared learning, open dialogue, and a deeper understanding of the lived experience of PH.

Vienna, Austria • September 14
ELF NETWORKING DAY
Staff members attended ELF's Networking Day ahead of the ERS Congress. The programme featured insightful presentations and discussions that highlighted the strength of patient advocacy and its growing influence in shaping health policies.

Vienna, Austria • September 8-11
ERS CONGRESS
Selected board and staff members participated in the large ERS Congress, an excellent opportunity to attend high-level scientific presentations and engage in face-to-face meetings across several committees and working groups, including ELF PAC, ELF IPAC, ELF PH PAG, ELHG, ERN-LUNG, and others.

Barcelona, Spain • November 6-10
APHEC (ANNUAL PH EUROPEAN CONFERENCE)
PHA Europe held its annual conference in November, featuring the Annual General Meeting followed by three additional days of presentations, workshops, and collaborative sessions.